Hims & Hers Health, Inc. (HIMS) falls on deep earnings miss
Hims & Hers Health, Inc. (HIMS) falls after a Q3 miss that went beyond the headline. This deep-dive examines weaker margins, softer guidance, shifting product mix, and the growth-versus-profit tradeoff behind the stock’s decline.
Hims & Hers Health (HIMS) sold off after reporting a deep Q3 earnings miss, with EPS of -$0.14 versus a $0.06 estimate and revenue of $890.4 million just below consensus. The bigger issue for investors was guidance: Q4 revenue and adjusted EBITDA both came in below expectations, while full-year 2026 EBITDA guidance was cut, signaling margin pressure is likely to persist despite 49% year-over-year sales growth.
Hims & Hers Health, Inc. (HIMS) falls after a Q3 earnings miss. EPS came in at -$0.14 versus a $0.06 consensus estimate, while revenue reached $890.4M against $892.9M; the latest regular-session close was $22.94, down 11.77%, on 48,695,597 shares.
Key Takeaways
HIMS posted Q3 EPS of -$0.14, missing the $0.06 analyst estimate. Revenue reached $890.4M, slightly below the $892.9M consensus.
Revenue grew 49% year over year, but gross margin fell to 57% from 74% as branded weight-loss products and international expansion changed the business mix.
Q4 revenue guidance of $875M to $895M sits below the $955.1M consensus. Adjusted EBITDA guidance of $70M to $90M also trails the $102.3M estimate.
Full-year 2026 adjusted EBITDA guidance fell to $257M to $277M from the prior $275M to $325M range.
Testosterone is scaling faster than any HIMS specialty outside weight loss, according to CEO Andrew Dudum, while the company plans injectable and oral TRT before year-end.
Analyst sentiment remains cautious. The consensus is Hold, with 7 Buy ratings and 13 Hold ratings. Morningstar focused on stronger revenue per subscriber but weaker near-term margins.
The central HIMS earnings story is a widening gap between sales growth and earnings power. Q3 revenue reached $890.4M, up 49% from a year earlier. That result also marked an increase from $750M in Q2 and $610M in Q1.
However, the top line missed consensus, and EPS remained negative. HIMS reported -$0.14 per share after -$0.37 in Q2 and -$0.40 in Q1. The company earned $0.09 per share in Q4 2025 and $0.07 in Q3 2025, so the latest result extends a three-quarter stretch of losses.
Net loss narrowed to $30M from $90M in each of the prior two quarters. That improvement is useful, but it did not offset the earnings miss because the business is carrying a less profitable revenue mix.
Gross margin provides the clearest explanation. The margin fell to 57% from 74% a year earlier. Reuters and Investing.com attributed the decline to HIMS shifting toward branded weight-loss drugs and expanding internationally. Revenue per subscriber is improving, but each dollar of sales now carries less gross profit.
That tradeoff matters because HIMS is moving beyond its earlier compounding-heavy model. Weight loss remains the largest strategic growth area, while testosterone is becoming a meaningful second engine. Dudum said testosterone was scaling faster than any specialty outside weight loss only three quarters after launch.
The company also reported more than 300,000 new subscribers and a global base approaching 3 million. Those figures support the growth case, but the Q3 margin shows the cost of serving customers through branded products, international operations, and more complex care categories.
The outlook makes the earnings reset more important than the revenue miss itself. HIMS expects Q4 revenue of $875M to $895M, below the $955.1M consensus. Adjusted EBITDA guidance of $70M to $90M is also below the $102.3M estimate. Full-year adjusted EBITDA guidance was cut to $257M to $277M from $275M to $325M.
Market Reaction and Analyst Response
The market treated the guidance gap as the main event. Reuters reported that shares fell more than 3% in volatile after-hours trading. The latest regular-session data showed a close at $22.94, down 11.77%, with volume of 48,695,597 shares versus an average of 10,865,496.
The move reflects a familiar market judgment: fast revenue growth does not protect a stock when the earnings path moves lower. HIMS still has a large subscriber base and a broad product strategy, but investors repriced the near-term economics after seeing lower margins and weaker forward EBITDA.
The current analyst consensus is Hold across 20 ratings, with 7 Buys, 13 Holds, and no Sell ratings. Benzinga's latest target snapshot showed an average price target of $31 across 14 analysts. JPMorgan's Cory Carpenter initiated coverage with a Neutral rating and a $32 target on September 11, 2026.
"The greater mix of branded weight-loss products is helping lift revenue per subscriber, but will continue to weigh on gross margins in the near term." - Keonhee Kim, Morningstar, cited by Reuters
That view captures the central analyst debate. The growth engine is working, but the old margin profile is not intact. Paul Cerro of Cedar Grove Capital Management offered a less alarmed interpretation.
"Margin compression was to be expected." - Paul Cerro, Cedar Grove Capital Management
Cerro's comment frames the selloff as a repricing of the business model rather than a collapse in demand. Still, the lower Q4 outlook gives analysts a concrete reason to reduce near-term earnings expectations.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
CEO Andrew Dudum used the HIMS earnings call to place the quarter inside a larger strategy built around AI, broader care categories, and a closed-loop customer relationship. His argument is that HIMS is building more than a telehealth storefront. It wants to combine clinicians, pharmacies, support teams, and AI inside one platform.
"Customer trust isn't something you can buy. It has to be earned." - Andrew Dudum, CEO, Earnings Call
Dudum said HIMS is making its platform completely AI-native. The company is adding AI talent, developing existing teams, and opening an AI research and development lab in Menlo Park. The strategy carries near-term investment, which fits the weaker adjusted EBITDA outlook.
The early operating data is specific. HERS weight-loss customers using the new AI care experience sent 3 times as many messages, while AI answered 80% of their questions. The system also reduced support tasks such as order updates and general side-effect questions by nearly 50%.
"We are making AI load-bearing, not decorative." - Mohamed ElShenawy, CTO, Earnings Call
The plain-English version is simple: HIMS wants AI to lower routine service work while allowing clinicians to focus on treatment decisions. That plan supports operating leverage over time, but Q3 shows the company is spending before the margin benefit fully arrives.
HIMS is also building infrastructure for more complex categories. Dudum cited more than 1 million square feet of pharmacy and lab testing facilities, along with experience in sterile compounding. The company plans access to already allowed peptides before year-end and is developing a broader peptide offering tied to clinical guidance and blood testing.
Bottom Line
HIMS still owns a powerful growth narrative, with 49% revenue growth, nearly 3 million subscribers, and expansion into weight loss, testosterone, peptides, and AI-enabled care. Yet the -$0.14 EPS result, 57% gross margin, and reduced EBITDA outlook show that growth is arriving with a real profitability cost.
For investors, the next phase of the HIMS story depends on whether subscriber growth and AI efficiency can restore operating leverage while the company expands into lower-margin categories. Until that balance improves, the Hold consensus and sharp price reaction remain grounded in the numbers.
Hims & Hers Health (HIMS) fell after reporting Q3 EPS of -$0.14, well below the $0.06 consensus estimate, and issuing weaker-than-expected guidance. The market also reacted to gross margin compression to 57% from 74% a year earlier and a reduced full-year EBITDA outlook.
+Did Hims & Hers beat revenue expectations in Q3?
No, Hims & Hers reported Q3 revenue of $890.4 million versus the $892.9 million consensus estimate. Revenue still grew 49% year over year, but it missed Wall Street expectations by a small margin.
+What was HIMS's Q4 guidance after the earnings report?
Hims & Hers guided Q4 revenue to $875 million to $895 million, below the $955.1 million consensus estimate. The company also guided adjusted EBITDA to $70 million to $90 million, which trailed the $102.3 million analyst estimate.
+What happened to Hims & Hers margins in Q3?
Gross margin fell to 57% in Q3 from 74% a year earlier. The company said the decline was tied to a heavier mix of branded weight-loss products and international expansion.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on HIMS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.